These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16720199)

  • 1. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
    Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
    Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Boyd K; Dearden CE
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
    Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
    Hillmen P
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
    Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.